chimeric antigen receptor-T cell therapy

CAR-T cell therapy helps man continue community advocacy

After Sylvester Pinckney's lymphoma returned, chimeric antigen receptor-T cell therapy at Mayo Clinic put his cancer back in remission.

Hope, time and new options after CAR-T cell therapy for multiple myeloma

After receiving CAR-T cell therapy at Mayo Clinic, Welsh-born John Cadwallader achieved remission and found new hope. He now receives care in the U.K. and is monitored by Mayo in the U.S. and London.

Understanding CAR-T cell therapy and its potential side effects

Dr. Mohamed Kharfan Dabaja discusses who is eligible for CAR-T cell therapy, the treatment process and its potential side effects.

CAR-T cell therapy restores hope for leukemia patient

After receiving CAR-T cell therapy for chronic lymphocytic leukemia through a clinical trial at Mayo Clinic, Jon Stahlecker is cancer free and feeling good.

Mayo Clinic researchers load CAR-T cells with oncolytic virus to treat solid cancer tumors

Researchers used a new immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors in mouse models.

What is chimeric antigen receptor-T cell therapy?

Learn about CAR-T cell therapy, a personalized treatment giving hope to patients diagnosed with various lymphomas.